An Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
Launched by PTC THERAPEUTICS · Feb 2, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Participants who completed the Treatment Period in the parent Phase 2a Study PTC518-CNS-002-HD (NCT05358717), fulfilled the enrollment criteria, and chose to enroll in this extension study will undergo baseline evaluations and be assessed for 30 additional months.
All participants will receive active PTC518 in this extension study. Participants who received PTC518 in the parent Study PTC518-CNS-002-HD will continue at the same dose level they received in that study in a blinded fashion (5, 10, or 20 milligrams \[mg\]). Participants who received placebo in the parent Study PTC518-CNS-002-HD...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant who has completed the Treatment Period in Study PTC518-CNS-002-HD.
- Exclusion Criteria:
- • Participants who have not previously completed the Treatment Period in Study PTC518-CNS-002-HD.
- • Note: Other inclusion and exclusion criteria may apply.
About Ptc Therapeutics
PTC Therapeutics is a biotechnology company dedicated to the discovery and development of innovative medicines for the treatment of rare diseases and cancer. With a strong focus on advancing its proprietary drug development pipeline, PTC Therapeutics employs cutting-edge science and technology to address unmet medical needs. The company collaborates with a network of academic institutions, patient advocacy groups, and industry partners to drive research initiatives and clinical trials aimed at improving patient outcomes. Committed to patient-centered care, PTC Therapeutics strives to bring transformative therapies to market that enhance the quality of life for individuals affected by challenging health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Innsbruck, , Austria
Leiden, , Netherlands
Madrid, , Spain
Cardiff, , United Kingdom
Barcelona, , Spain
Berlin, , Germany
Manchester, , United Kingdom
Westmead, , Australia
Angers, , France
Münster, , Germany
Barakaldo, , Spain
Clayton, , Australia
Bologna, , Italy
Barcelona, Cataluña, Spain
Marseille, , France
Paris, , France
Bochum, , Germany
Ulm, , Germany
London, , United Kingdom
Montreal, , Canada
Ottawa, , Canada
Vancouver, , Canada
Milan, , Italy
San Giovanni Rotondo, , Italy
Christchurch, , New Zealand
Burgos, , Spain
Birmingham, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported